3-(2-dimethylamino-ethyl)-indol-6-ylamine | 91646-27-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(2-dimethylamino-ethyl)-indol-6-ylamine
• 英文别名: 6-amino-3-(2-dimethylaminoethyl)-1H-indole；6-Amino-3-<2-dimethylamino-ethyl>-indol；6-Amino-3-(2-dimethylaminoethyl)indole；3-[2-(dimethylamino)ethyl]-1H-indol-6-amine
• CAS: 91646-27-4
• 化学式: C₁₂H₁₇N₃
• 分子量: 203.287
• InChiKey: VMKMTGSIPCKLSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  45
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,5-二氯苯磺酰氯 、 3-(2-dimethylamino-ethyl)-indol-6-ylamine 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以65%的产率得到6-bis(3,5-dichlorobenzenesulfonyl)amino-3-(2-(dimethylamino)ethyl)-1H-indole
  参考文献：
  名称：

  [EN] SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS
  [FR] COMPOSES D'INDOLE SUBSTITUES ET UTILISATION DE CEUX-CI COMME MODULATEURS DES RECEPTEURS 5-HT6

  摘要：

  本发明涉及通式I的取代吲哚化合物，其制备方法，包含取代吲哚化合物的药物，以及利用取代吲哚化合物制备药物，该药物适用于预防和/或治疗至少部分通过5-HT6受体介导的紊乱或疾病。

  公开号：

  WO2006024535A1

文献信息

• Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2116546A1

  公开（公告）日：2009-11-11

  The invention relates to compounds having pharmacological activity towards the 5-HT6 receptor, and more particularly to some N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT6 is involved.

  该发明涉及具有对5-HT6受体具有药理活性的化合物，更特别地涉及一些N-苯基-2,3-二氢咪唑[2,1-b]噻唑-5-磺酰胺衍生物，以及制备这些化合物的方法，包括含有它们的药物组合物，以及它们用于治疗和/或预防5-HT6参与的疾病。
• Indole derivatives
  申请人：Pfizer Inc

  公开号：US05639752A1

  公开（公告）日：1997-06-17

  Compounds of the formula ##STR1## wherein Z is ##STR2## R.sub.1 is ##STR3## X is O, NH, or S; A, B, D, E, and F are each independently C, N, O, or S; wherein the remaining variables are defined in the specification, and the pharmaceutically acceptable salts thereof. These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

  化合物的公式为##STR1##其中Z为##STR2##R.sub.1为##STR3##X为O、NH或S；A、B、D、E和F各自独立地为C、N、O或S；其余变量在说明书中定义，并且其药学上可接受的盐。这些化合物是有用的心理治疗药物，是有效的5-羟色胺（5-HT1）激动剂，可用于治疗抑郁症、焦虑症、进食障碍、肥胖症、药物滥用、簇头痛、偏头痛、疼痛、慢性阵发性半枕状神经痛和与血管紊乱相关的头痛以及由于5-羟色胺能神经递质缺乏引起的其他疾病。这些化合物也可用作中枢作用的降压药和扩血管药。
• SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS
  申请人：Merce Vidal Ramon

  公开号：US20070213326A1

  公开（公告）日：2007-09-13

  The present invention relates to substituted indole compound of general formula I, a process for their preparation, medicaments comprising substituted indole compounds as well as the use of substituted indole compounds for the preparation of medicaments, which are suitable e.g. for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT 6 receptors.

  本发明涉及通式I的取代吲哚化合物、其制备方法、含有取代吲哚化合物的药物以及利用取代吲哚化合物制备药物的用途，其中所述药物适用于预防和/或治疗至少部分通过5-HT6受体介导的紊乱或疾病。
• Substituted indole compounds and their use as 5-HT6 receptor modulators
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2308871A1

  公开（公告）日：2011-04-13

  The present invention relates to substituted indole compound of general formula I, a process for their preparation, medicaments comprising substituted indole compounds as well as the use of substituted indole compounds for the preparation of medicaments, which are suitable e.g. for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT6 receptors.

  本发明涉及通式I的取代吲哚化合物、其制备工艺、包含取代吲哚化合物的药物以及使用取代吲哚化合物制备药物，这些药物适用于预防和/或治疗至少部分通过5-HT6受体介导的紊乱或疾病。
• US5639752A
  申请人：——

  公开号：US5639752A

  公开（公告）日：1997-06-17